Preclinical evaluation of (S)-[18F]GE387, a novel 18-kDa translocator protein (TSPO) PET radioligand with low binding sensitivity to human polymorphism rs6971

Nisha K. Ramakrishnan, Matthew Hird, Stephen Thompson, David J. Williamson, Luxi Qiao, David R. Owen, Allen F. Brooks, Peter J. H. Scott, Sergio Bacallado, John T. O’Brien, Franklin I. AigbirhioEuropean 2021 · DOI

TL;DR

This paper introduces (S)-[<sup>18</sup>F]GE387, a new PET radioligand for imaging neuroinflammation, which shows promising low sensitivity to a common human genetic polymorphism that affects other TSPO tracers. Preclinical studies in rats and non-human primates demonstrate its ability to detect inflammation and favorable brain uptake, suggesting it could be a valuable tool for human neuroinflammation research.

What Problem Does This Paper Address?

Neuroinflammation, the brain's immune response, is implicated in a wide range of neurological disorders, from traumatic brain injury to neurodegenerative diseases like Alzheimer's. Positron Emission Tomography (PET) is a powerful tool for visualizing and quantifying this inflammation in vivo. A key target for PET imaging of neuroinflammation is the 18-kDa translocator protein (TSPO), which is upregulated on activated microglia (the brain's immune cells) during inflammation.

However, existing TSPO PET tracers have faced challenges. The first-generation tracer, [<sup>11</sup>C]PK11195, suffers from poor signal-to-noise and a short half-life. Second-generation tracers, while offering improvements, often exhibit significant variability in binding affinity among individuals due to a common genetic polymorphism in the TSPO gene (rs6971). This polymorphism leads to different "binding affinity" groups (High Affinity Binders - HABs, Low Affinity Binders - LABs, and Mixed Affinity Binders - MABs), complicating data interpretation and often requiring exclusion of certain individuals from studies. This limitation hinders the broad applicability and translation of TSPO PET imaging to diverse human populations. The paper aims to address this by evaluating a novel TSPO radioligand, GE387, specifically designed to have low sensitivity to this rs6971 polymorphism.

Methods

The study employed a multi-faceted approach to evaluate the preclinical performance of (S)-[<sup>18</sup>F]GE387 and its enantiomer (R)-[<sup>18</sup>F]GE387:

  • Radiosynthesis: The two enantiomers were synthesized from their respective pure precursors using a previously established method.
  • In Vivo PET Imaging in Animals:
    • Dynamic PET scans were performed in male Wistar rats and female rhesus macaques to assess the radioligands' brain uptake, distribution, and clearance over time.
  • Blocking studies were conducted in rats by pre-treating them with a known TSPO ligand, (R)-PK11195, to confirm the specific binding of (S)-[<sup>18</sup>F]GE387 to TSPO.
  • Neuroinflammation Model: A rat model of neuroinflammation was induced by injecting lipopolysaccharide (LPS) into one striatum, with the contralateral striatum serving as a control. PET scans were then used to assess the radioligand's ability to differentiate inflamed from normal brain regions.
  • Kinetic Modeling: Two-tissue compartment models (2-TCM) were used to analyze the dynamic PET data, providing quantitative parameters like total volume of distribution (V<sub>T</sub>) and binding potential (BP<sub>ND</sub>).
  • Competition Binding Assay: A in vitro competition binding assay was performed using genotyped human cortical brain tissue (from both HABs and LABs) to directly assess the binding affinity of (S)-GE387 and its sensitivity to the rs6971 polymorphism. This involved incubating the tissue with a known radioligand ([<sup>3</sup>H]PK11195) and varying concentrations of unlabeled (S)-GE387 to determine IC<sub>50</sub> and subsequently K<sub>i</sub> values.

Datasets

  • Animal Data: PET imaging data were acquired from male Wistar rats and female rhesus macaques.
  • Human Brain Tissue: Genotyped human cortical brain tissue was obtained from the UK MS brain bank, representing both High Affinity Binders (HABs) and Low Affinity Binders (LABs) for TSPO ligands.

Key Insights and Ideas

  • Low Polymorphism Sensitivity is Key: The central hypothesis is that GE387's low sensitivity to the rs6971 polymorphism will make it a more universally applicable TSPO PET tracer, overcoming a major hurdle in current neuroinflammation imaging.
  • Enantiomer Specificity Matters: The study focuses on the (S)-enantiomer, suggesting that stereochemistry plays a crucial role in the ligand's binding properties and potential for clinical translation.
  • Brain vs. Periphery Uptake: The radioligands show low uptake in the healthy brain but higher uptake in TSPO-rich peripheral organs. This difference is important for understanding background signal and potential off-target binding.
  • LPS Model as a Proxy for Human Inflammation: The use of an LPS-induced neuroinflammation model in rats serves as a critical preclinical step to demonstrate the tracer's ability to detect inflammation in a controlled setting before human trials.

Key Results

  • Favorable Brain Kinetics: Both (S)- and (R)-[<sup>18</sup>F]GE387 showed rapid brain uptake in rats and non-human primates, reaching peak levels within 1-2 minutes, followed by a relatively slow washout.
  • TSPO-Specific Binding Confirmed: Pre-treatment with (R)-PK11195 significantly blocked the uptake of (S)-[<sup>18</sup>F]GE387 in TSPO-rich regions, including the olfactory bulb (a region with constitutive TSPO expression) and peripheral organs, confirming specific TSPO binding.
  • Detection of Neuroinflammation: In the LPS-induced neuroinflammation model, (S)-[<sup>18</sup>F]GE387 demonstrated a significantly higher uptake in the inflamed striatum compared to the contralateral control striatum, with an SUV ratio of 2.7.
  • Low Polymorphism Sensitivity Demonstrated: The in vitro competition binding assay using human brain tissue revealed a low LAB to HAB binding ratio of 1.8:1 for (S)-GE387, confirming its reduced sensitivity to the rs6971 polymorphism. This is a significant improvement over many other second-generation TSPO tracers.
  • Metabolite Profile: (S)-[<sup>18</sup>F]GE387 exhibited a better metabolite profile in plasma and brain compared to its R-enantiomer, with a higher percentage of intact parent radioligand remaining at 60 minutes.

Limitations and Future Work

  • Brain Metabolite Analysis: While plasma metabolite analysis was performed, the paper notes that the brain metabolite analysis involved a single solvent extraction, which might skew results towards more polar metabolites. Further detailed brain metabolite identification is suggested.
  • Human Studies Needed: The study is preclinical. The authors emphasize that further evaluation, including metabolite identification, dosimetry, and toxicology studies, is required to support the translation of (S)-[<sup>18</sup>F]GE387 to human clinical use. The ultimate validation will come from human subject studies to confirm its suitability for assessing neuroinflammation across diverse genotypes.
  • Peripheral Binding: While beneficial for blocking studies, the higher uptake in peripheral TSPO-rich organs might require careful consideration in human imaging to avoid potential confounding signals.
  • Comparison with Other Tracers: While comparisons are made to other tracers, the authors suggest that further direct comparisons in specific neuroinflammatory models would be beneficial.

The authors conclude that (S)-[<sup>18</sup>F]GE387 warrants further evaluation in human subjects due to its favorable kinetics, ability to detect neuroinflammation, and crucially, its low sensitivity to the TSPO polymorphism, making it a promising candidate for widespread use in neuroinflammation research.

Summary updated

Abstract

We established that (S)-[<sup>18</sup>F]GE387 has favourable kinetics in healthy rats and non-human primates and that it can distinguish inflamed from normal brain regions in the LPS model of neuroinflammation. Crucially, we have reconfirmed its low sensitivity to the TSPO polymorphism on genotyped human brain tissue. Based on these factors, we conclude that (S)-[<sup>18</sup>F]GE387 warrants further evaluation with studies on human subjects to assess its suitability as a TSPO PET radioligand for assessing neuroinflammation.
BibTeX
@inproceedings{ramakrishnan2021preclinical,
  author = {Nisha K. Ramakrishnan and Matthew Hird and Stephen Thompson and David J. Williamson and Luxi Qiao and David R. Owen and Allen F. Brooks and Peter J. H. Scott and Sergio Bacallado and John T. O’Brien and Franklin I. Aigbirhio},
  title = {{Preclinical evaluation of (S)-[18F]GE387, a novel 18-kDa translocator protein (TSPO) PET radioligand with low binding sensitivity to human polymorphism rs6971}},
  booktitle = {European},
  year = {2021},
  doi = {10.1007/s00259-021-05495-w},
}
Figure